1. El-Salhy M. Recent developments in the pathophysiology of irritable
bowel syndrome. World J Gastroenterol. 2015;21:7621–36.
2. Kubo M, Fujiwara Y, Shiba M, Kohata Y, Yamagami H, Tanigawa T, et al. Differences between risk factors among irritable bowel syndrome subtypes
in Japanese adults. Neurogastroenterol Motil. 2011;23:249–54.
3. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of
irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–60.
4. Kanazawa M, Endo Y, Whitehead WE, Kano M, Hongo M, Fukudo S.
Patients and non-consulters with irritable bowel syndrome reporting a
parental history of bowel problems have more impaired psychological
distress. Dig Dis Sci. 2004;49:1046–53.
5. Kaji M, Fujiwara Y, Shiba M, Kohata Y, Yamagami H, Tanigawa T, et al.
Prevalence of overlaps between GERD, FD and IBS and impact on healthrelated quality of life. J Gastroenterol Hepatol. 2010;25:1151–6.
6. Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther.
2003;18:671–82.
7. El-Salhy M. Recent advances in the diagnosis of irritable bowel syndrome.
Expert Rev Gastroenterol Hepatol. 2015;9:1161–74.
8. Ng QX, Soh AYS, Loke W, Venkatanarayanan N, Lim DY, Yeo WS. A metaanalysis of the clinical use of curcumin for irritable bowel syndrome (IBS).
J Clin Med. 2018;7:298.
9. Ng QX, Soh AY, Lim DY, Yeo WS. Agomelatine, a novel therapeutic option
for the management of irritable bowel syndrome. J Clin Pharm Ther.
2018;43:752–6.
10. Malikowski T, Khanna S, Pardi DS. Fecal microbiota transplantation for
gastrointestinal disorders. Curr Opin Gastroenterol. 2017;33:8–13.
11. Sundin J, Ohman L, Simren M. Understanding the gut microbiota in
inflammatory and functional gastrointestinal diseases. Psychosom Med.
2017;79:857–67.
12. Sundin J, Rangel I, Fuentes S, Heikamp-de Jong I, Hultgren-Hörnquist
E, de Vos WM, et al. Altered faecal and mucosal microbial composition
in post-infectious irritable bowel syndrome patients correlates with
mucosal lymphocyte phenotypes and psychological distress. Aliment
Pharmacol Ther. 2015;41:342–51.
13. Ohman L, Tornblom H, Simren M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol.
2015;12:36–49.
14. Biedermann L, Rogler G. The intestinal microbiota: its role in health and
disease. Eur J Pediatr. 2015;174:151–67.
15. Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome
and intestinal microbiota. World J Gastroenterol. 2014;20:2470–81.
16. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut
microbiota in disease. Microb Ecol Health Dis. 2015;26:26191.
17. Osadchiy V, Martin CR, Mayer EA. The gut-brain axis and the microbiome: mechanisms and clinical implications. Clin Gastroenterol Hepatol.
2019;17:322–32.
18. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and
functional bowel disorders. Gastroenterology. 2014;146:1500–12.
19. Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation
(FMT) an effective treatment for patients with functional gastrointestinal
disorders (FGID)? Neurogastroenterol Motil. 2015;27:19–29.
20. El-Salhy M, Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome. Expert Rev Gastroenterol Hepatol.
2018;12:439–45.
21. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM,
et al. Duodenal infusion of donor feces for recurrent Clostridium Difficile.
N Engl J Med. 2013;368:407–15.
22. Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW,
et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled
trial. Lancet Gastroenterol Hepatol. 2019;4:675–85.
23. Halkjaer SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH,
et al. Faecal microbiota transplantation alters gut microbiota in patients
with irritable bowel syndrome: Results from a randomized, double-blind
placebo controlled study. Gut. 2018;67:2107–15.
24. El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel
Page 10 of 11
25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. syndrome in a randomised, double-blind, placebo-controlled study. Gut.
2020;69:859–67.
Johnsen PH, Hilpusch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC,
et al. Faecal microbiota transplantation versus placebo for moderate-tosevere irritable bowel syndrome: a double-blind, randomized, placebocontrolled, parallel-group, single-centre trial. Lancet Gastroenterol
Hepatol. 2018;3:17–24.
Holvoet T, Joossens M, Vázquez-Castellanos JF, Christiaens E, Heyerick L,
Boelens J, et al. Fecal microbiota transplantation reduces symptoms in
some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled
randomized trial. Gastroenterology. 2021;160:145–57.
Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillilä M, Punkkinen J, et al.
Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
Aliment Pharmacol Ther. 2020;51:1321–31.
Holster S, Lindqvist CM, Repsilber D, Salonen A, de Vos WM, König J,
et al. The effect of allogenic versus autologous fecal microbiota transfer
on symptoms, visceral perception and fecal and mucosal microbiota
in irritable bowel syndrome: a randomized controlled study. Clin Transl
Gastroenterol. 2019;10: e00034.
Nishijima S, Suda W, Oshima K, Seok-Won K, Hirose Y, Morita H, et al. The
gut microbiome of healthy Japanese and its microbial and functional
uniqueness. DNA Res. 2016;23:125–33.
Mizuno S, Masaoka T, Naganuma M, Kishimoto T, Kitazawa M, Kurokawa S,
et al. Bifidobacterium-rich fecal donor may be a positive predictor for successful fecal microbiota transplantation in patients with irritable bowel
syndrome. Digestion. 2017;96:29–38.
Simren M, Palsson OS, Whitehead WE. Update on Rome IV criteria for
colorectal disorders: implications for clinical practice. Curr Gastroenterol
Rep. 2017;19:15.
Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R,
et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569–80.
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring
system: a simple method of monitoring irritable bowel syndrome and its
progress. Aliment Pharmacol Ther. 1997;11:395–402.
Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel
disorders. Gastroenterology. 2016;150:1393–407.
Yamamoto K, Ishigami M, Honda T, Takeyama T, Ito T, Ishizu Y, et al. Influence of proton pump inhibitors on microbiota in chronic liver disease
patients. Hepatol Int. 2019;13:234–44.
Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello
EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335–6.
Edgar RC. Search and clustering orders of magnitude faster than BLAST.
Bioinformatics. 2010;26:2460–1.
Navas-Molina JA, Peralta-Sánchez JM, González A, McMurdie PJ, VázquezBaeza Y, Xu Z, et al. Advancing our understanding of the human microbiome using QIIME. Methods Enzymol. 2013;531:371–444.
DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, et al.
Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006;72:5069–72.
Dhariwal A, Chong J, Habib S, King I, Agellon LB, Xia J. MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual and metaanalysis of microbiome data. Nucleic Acids Res. 2017;45:W180–8.
Segata N, Izard J, Walron L, Gevers D, Miropolsky L, Garrett W, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome
Biol. 2011;12:60.
Myneedu K, Deoker A, Schmulson MJ, Bashashati M. Fecal microbiota
transplantation in irritable bowel syndrome: a systematic review and
meta-analysis. United European Gastroenterol J. 2019;7:1033–41.
El-Salhy M, Hausken T, Hatlebakk JG. Current status of fecal microbiota
transplantation for irritable bowel syndrome. Neurogastroenterol Motil.
2021;33: e14157.
Chen QY, Tian HL, Yang B, Lin ZL, Zhao D, Ye C, Zhang XY, Qin HL, Li N.
Effect of intestinal preparation on the efficacy and safety of fecal microbiota transplantation treatment. Zhonghua Wei Chang Wai Ke Za Zhi.
2020;23:48–55.
Hamazaki et al. BMC Gastroenterology
(2022) 22:342
Page 11 of 11
45. El-Salhy M, Casen C, Valeur J, Hausken T, Hatlebakk JG. Responses to faecal microbiota transplantation in female and male patients with irritable
bowel syndrome. World J Gastroenterol. 2021;27:2219–37.
46. Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, et al. Systematic review:
adverse events of fecal microbiota transplantation. PLoS ONE. 2016;11:
e0161174.
47. Wilson BC, Vatanen T, Cutfield WS, O’Sullivan JM. The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol.
2019;9:2.
48. Jalanka J, Mattila E, Jouhten H, Hartman J, de Vos WM, Arkkila P, et al.
Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for Recurrent
Clostridium Difficile Infection. BMC Med. 2016;14:155.
49. Seekatz AM, Aas J, Gessert CE, Rubin TA, Saman DM, Bakken JS, et al.
Recovery of the gut microbiome following fecal microbiota transplantation. MBio. 2014;5:e00893-14.
50. Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI,
et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol.
2010;105:2420–8.
51. Chelakkot C, Choi Y, Kim DK, Park HT, Ghim J, Kwon Y, et al. Akkermansia
muciniphila-derived extracellular vesicles influence gut permeability
through the regulation of tight junctions. Exp Mol Med. 2018;50: e450.
52. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al.
Cross-talk between Akkermansia muciniphila and intestinal epithelium
controls diet-induced obesity. Proc Natl Acad Sci USA. 2013;110:9066–71.
53. Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. Akkermansia muciniphila
protects against atherosclerosis by preventing metabolic endotoxemiainduced inflammation in Apoe-/-mice. Circulation. 2016;133:2434–46.
54. Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S,
et al. Supplementation with Akkermansia muciniphila in overweight and
obese human volunteers: a proof-of-concept exploratory study. Nat Med.
2019;25:1096–103.
55. Cruz-Aguliar RM, Wantia N, Clavel T, Vehreschild MJGT, Buch T, Bajbouj
M, et al. An open-labeled study on fecal microbiota transfer in irritable
bowel syndrome patients reveals improvement in abdominal pain associated with the relative abundance of Akkermansia Muciniphila. Digestion.
2019;100:127–38.
56. Chassard C, Dapoigny M, Scott KP, Crouzet L, Del’homme C, Marquet
P, et al. Functional dysbiosis within the gut microbiota of patients
with constipated-irritable bowel syndrome. Aliment Pharmacol Ther.
2012;35:828–38.
57. Terada Y, Kawabata A. H2S and pain: a novel aspect for processing of
somatic, visceral and neuropathic pain signals. Handb Exp Pharmacol.
2015;230:217.
58. Hatakeyama Y, Takahashi K, Tominaga M, Kimura H, Ohta T. Polysulfide
evokes acute pain through the activation of nociceptive TRPA1 in mouse
sensory neurons. Mol Pain. 2015;11:24.
59. Huang HL, Chen HT, Luo QL, Xu HM, He J, Li YQ, et al. Relief of irritable
bowel syndrome by fecal microbiota transplantation is associated with
changes in diversity and composition of the gut microbiota. J Dig Dis.
2019;20:401–8.
60. Bashashati M, Rezaei N, Shafieyoun A, McKernan DP, Chang L, Öhman
L, et al. Cytokine imbalance in irritable bowel syndrome: a systematic
review and meta-analysis. Neurogastroenterol Motil. 2014;26:1036–48.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ready to submit your research ? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
...
論文の公開元へ
